Prestige Consumer Healthcare (PBH) to Release Earnings on Thursday

Key Points

• Prestige Consumer Healthcare is set to release its Q1 2026 earnings data on August 7th, expecting earnings of $1.01 per share and revenue of $260.71 million.
• In its last quarterly earnings report, Prestige reported $1.32 EPS, exceeding estimates and showing a 7.0% year-over-year revenue increase.
• Institutional investors hold 99.95% of Prestige’s stock, with several hedge funds increasing their stakes significantly in the past quarter.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) is anticipated to issue its Q1 2026 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $1.01 per share and revenue of $260.71 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.700-4.820 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same quarter in the prior year, the business posted $1.02 EPS. The business's revenue was up 7.0% compared to the same quarter last year. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH traded up $0.58 on Monday, reaching $74.30. 119,308 shares of the company's stock were exchanged, compared to its average volume of 365,993. The company has a fifty day moving average of $80.65 and a 200-day moving average of $82.33. Prestige Consumer Healthcare has a twelve month low of $64.94 and a twelve month high of $90.04. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 2.21 and a beta of 0.43. The company has a current ratio of 4.20, a quick ratio of 2.82 and a debt-to-equity ratio of 0.55.

Wall Street Analyst Weigh In

PBH has been the topic of several analyst reports. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $93.33.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. lifted its stake in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Prestige Consumer Healthcare by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company's stock valued at $2,535,000 after acquiring an additional 1,289 shares during the last quarter. AQR Capital Management LLC raised its stake in Prestige Consumer Healthcare by 11.9% during the first quarter. AQR Capital Management LLC now owns 30,056 shares of the company's stock worth $2,558,000 after buying an additional 3,200 shares during the last quarter. Jane Street Group LLC raised its stake in Prestige Consumer Healthcare by 204.0% during the first quarter. Jane Street Group LLC now owns 104,802 shares of the company's stock worth $9,010,000 after buying an additional 70,330 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company's stock worth $46,997,000 after buying an additional 120,965 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.